Women who had depressive symptoms during their third trimester of pregnancy, or persistently before and after giving birth, were twice as likely to have babies with very low levels of immunoglobulin A.
Patients with residual depressive symptoms who received online mindfulness-based cognitive therapy (MBCT) plus usual care demonstrated significant gains in depression and functional outcomes, compared with patients who received usual care only.
AXS-05, an investigational modulated-delivery tablet combining dextromethorphan and bupropion, significantly improved symptoms of depression in patients with major depressive disorder (MDD) in a recent phase 3 trial, announced developer Axsome Therapeutics Inc.
A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.
SAN DIEGO—Psilocybin-assisted psychotherapy appears to have a beneficial and lasting effect on patient mood, but possible approval of the treatment remains some time away, a researcher said at Psych Congress 2019.